Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Retatrutide for Sale > High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - large image1
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - image1
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - image2
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - image3
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - image4
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - image5
High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack buy - image6

High Quality Retatrutide Peptide Powder with Professional Packaging Service Jack

7482 Inquiries

Unit Price:

$5/UNIT FOB

Get Latest Price
CAS No.:

2381089-83-2

Grade:

Pharmaceutical

Content:

99%

Port:

Hong Kong

Brand:

HUATAI

Packaging:

10vial

Price valid (until):

2026-11-11

Company Type:
Trader
Location:
China
Payment Terms:
TT against B/L draft before shipment,100% TT in advance
Average Lead Time:
1 days
Qualification:
Main Products:

Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide

  • Product Details

  • Seller Information

  • Inquiry History

  • Description


      Product Detail  


    Contact us  

    whatsapp: 

    +852 4707 2490 Jack 

    Retatrutide is a triple glucagon, GIP, and receptor agonist. Retatrutide showed glucose control and weight loss in patients with type 2 diabetes mellitus (T2DM). Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor .Retatrutide can be used for the research of obesity. Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides.

    Funtion

    1. 1.Preclinical research indicates Retatrutide exerts regulatory effects on mental and emotional activities, showing potential value for related physiological and pharmacological research. 2.Retatrutide possesses neuroprotective properties, which can be applied in the research and mechanism exploration of neurodegenerative conditions like Alzheimer’s and Parkinson’s disease. 3.Relevant animal studies demonstrate that Retatrutide helps optimize learning and memory performance, presenting research prospects for cognitive function regulation.
    2. 4.Preclinical studies have verified that Retatrutide has analgesic bioactivity, offering research reference for the study of chronic discomfort regulation.
    3. 5.Animal experiments confirm that Retatrutide can accelerate tissue repair progress, with promising research potential as an active substance for wound recovery research.
    4. Application
    5. 1.Retatrutide is widely applied in pharmaceutical research and related biochemical studies.
    6. 2.Retatrutide belongs to a class of bioactive peptide compounds.
    7. 3.Retatrutide acetate can inhibit GCGR, GIPR and GLP-1R.
    8. 4.Retatrutide acetate acts on glucagon receptors to regulate physiological metabolism and energy expenditure.
    9. 5.Retatrutide acetate can be used in physiological and metabolic mechanism research
    ECHEMI Editorial Reference
    Retatrutide is a novel triple agonist peptide of the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide inhibits human GCGR, GIPR and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively and mouse GCGR, GIPR, and GLP-1R with EC50 values of 2.32, 0.191 and 0.794 nM, respectively. It is an important tool for obesity research.Retatrutide potently activates the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion through activity at the GIP receptor (GIPR) or the GLP-1R.Retatrutide is a synthetic peptide with glucose-lowering effects. It is an antidiabetic agent against type 2 diabetes (T2D), stimulating insulin and suppressing glucagon secretion in a glucose-dependent manner.Retatrutide was also shown to delay gastric emptying, lower fasting and postprandial glucose concentration, decrease food intake and reduce body weight in patients with type 2 diabetes.
    Retatrutide (LY-3437943) was discovered by the American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors) for obesity. The 2024 Lasker~DeBakey Clinical Medical Research Award has been given to Joel Habener and Svetlana Mojsov for their discovery of a new hormone GLP-1(7-37) and to Lotte Knudsen for her role in developing sustained acting versions of this hormone as a treatment for obesity.

    Basic Info
    Product Name:

    Retatrutide

    Other Name:

    Retatrutide;GIPR/GLP-1R;LY3437943Retatrutide;Retalutide;Retatrutide (sodium salt);Retatrutide RT5;retatrutide 5mg;Retatratide

    CAS No.:

    2381089-83-2

    InChIKeys:

    MLOLQJNKXBNWFW-SAGGEDDASA-N

    Molecular Weight:

    0

    EC Number:

    200-001-8

    Color/Form:

    White lyophilized

    Characteristics
    Water Solubility:

    Soluble in water (5mg/ml).

    Storage Conditions:

    -20°C

    Critical Temperature & Pressure:

    -20°C

    Research
    Class:

    Triple agonist — GCGR, GIPR, GLP-1R

    Status:

    Investigational (Phase 3)

    Mechanism:

    Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.

    EC50 (Human GCGR):

    5.79 nM

    EC50 (Mouse GIPR):

    0.191 nM

    EC50 (Mouse GLP1R):

    0.794 nM

    EC50 (Mouse GCGR):

    2.32 nM

    EC50 (Human GLP1R):

    0.775 nM

    EC50 (Human GIPR):

    0.0643 nM

    Source:

    Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI

    Clinical Development:

    NCT04881760; NCT05882045; NCT06354660

    References
    ChEMBL:

    CHEMBL5095485

    DrugBank:

    DB18993

    KEGG DRUG:

    D12430

    PubChem:

    PubChem

    Disclaimer:

    Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    Tirzepatide,Retatrutide,NAD+,Samaglutide,GHK-CU,cagrilintide

    Location:

    1502A1, Building 4, Xinyuanxin Center, No. 3 Huaxin Road, Dongfeng Street, Licheng District, Jinan City, Shandong Province

    Payment Terms:

    TT against B/L draft before shipment,100% TT in advance

    Average lead Time:

    1 days

    Total Annual Revenue:

    $10 million-$25 million

    Total Employees:

    51-100

    Year of Establishment:

    2026

    Company Certificates
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA
    • HUATAI PEPTIDESCOA COA

    COMPANY INTRODUCTION

    20 years of dedicated work in the peptide industry

    15 Years of Industry Experience

    We have been a high-tech company focused on the development, production, and marketing of various peptide products

     for 15 years. Through advanced laboratories and strict quality control, our internationally certified products are safe and 

    effective.


    Clients in Europe, the USA, Southeast Asia, and the Middle East

    As a global trading company, we serve clients across Europe, the USA, Southeast Asia, the Middle East, and beyond, providing

     customized solutions. Committed to "technology leading Health", we aim to innovate and deliver high-quality health products 

    worldwide.


    3,000sqm Factory with 60 Employees

    We have a factory covering 3,000 square meters and housing 60 employees to guarantee the highest quality all the time. We hired 

    three quality auditors with three years of experience. They meticulously inspect each item at every production stage.


    Contact Us Now

    Our products are exported to more than 130 countries and regions, which can be delivered fast within 5-14 days. We can provide

     OEM/ODM support to our customers. We have 10 professional after-sales staff to make 24-hour responses to our customers. 

    Contact us now to learn more. We hope to establish stable and strategic long-term business relationships with domestic and 

    foreign suppliers and customers, jointly pursuing a better future.


  • Inquiry History
    7482 Inquiries
    Country Product Purchase Quantity Date Posted
    Lithuania

    Retatrutide

    30 MG Oct 27, 2026
    United States

    Retatrutide

    10 MG Oct 27, 2026
    Greece

    Retatrutide

    30 MG Oct 27, 2026
    Germany

    Retatrutide

    20 MG Oct 27, 2026
    Canada

    Retatrutide

    30 MG Oct 27, 2026
    United States

    retatrutide

    40 MG Oct 27, 2026
    Spain

    Retatrutide

    30 MG Oct 27, 2026
    United Kingdom

    Retatrutide

    20 MG Oct 27, 2026
    United States

    Retatrutide

    40 MG Oct 27, 2026
    United States

    Retatrutide

    50 MG Oct 27, 2026
    United States

    retatrutide

    30 MG Oct 27, 2026
    United States

    retatrutide

    200 MG Oct 27, 2026
    Spain

    retatrutide

    200 MG Oct 27, 2026
    United States

    Retatrutide

    100 PCS Oct 27, 2026
    New Zealand

    Retatrutide

    20 PCS Oct 27, 2026
    Netherlands

    Retatrutide

    100 20' Fcl Oct 27, 2026
    United States

    Retatrutide

    300 MG Oct 27, 2026
    Canada

    Retatrutide

    1 G Oct 26, 2026
    Switzerland

    Retatrutide

    1 KG Oct 26, 2026
    United States

    Retatrutide

    10 MG Oct 26, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.